Haruo Naito, Eisai CEO (The Yomiuri Shimbun via AP Images)
Eisai eyes long game for Leqembi amid ‘dramatically’ increasing patient use
Full US approval of Biogen and Eisai’s Alzheimer’s drug Leqembi — and as a result, broad Medicare coverage — has led to a surge in uptake, Eisai …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
